Johnson & Johnson
NYSE:JNJPharmaNew Brunswick, NJ, United States · Est. 1886 · 132,000 employees
Diversified healthcare company with pharmaceutical, medical device, and consumer health segments.
85
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
103
Indications↗
Distinct diseases across all programs
1,922
Clinical Trials↗
All sponsored trials (all statuses)
79
Orange Book Patents
Across 11 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
85 drugs in development
Approved5
Phase 338
Phase 221
Phase 129
Preclinical19
By Therapeutic Area
top 6
Oncology
5246%
Immunology
109%
Gastroenterology
76%
Cardiovascular
54%
Ophthalmology
54%
Neurology
54%
R&D Momentum
95/100
Pipeline Velocity
73/100
Trial Completion Rate
86/100
Pipeline Concentration
25/100
Pipeline Freshness
62/100
Strategic Signals
- ↗Active in Infectious Disease but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Sep 18, 2026
Completed
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations
Sep 18, 2026
Suspended
TMC207-TIDP59-C211: A Phase 2, Open-label, Multicenter, Single-arm Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Anti-mycobacterial Activity of TMC207 in Combination With a Background Regimen (BR) of Multidrug Resistant Tuberculosis (MD
Sep 15, 2026
Active, not recruiting
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Sep 15, 2026
Recruiting
Long-term Extension Study for Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies
Sep 11, 2026
Recruiting
A Phase 1, First-in-Human Study of a Novel CD79bxCD20xCD3 Trispecific Antibody in B-Cell Non-Hodgkin Lymphoid Malignancies (NHLs)
Sep 11, 2026
Recruiting
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ 88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms
Earlier
Sep 4, 2026TrialPhase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Sep 2, 2026TrialA Phase 1 Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
3 more events
Sep 1, 2026TrialA Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
Sep 1, 2026TrialCNTO1959UCO3001: A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
Sep 1, 2026TrialA Randomized, Open-label, Phase 3 Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Subjects With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).
Details
Company Info
Company Overview
$425.0B
Mkt Cap
$85.2B
Revenue
$22.8B
Cash
CEOJoaquin Duato
Founded1886
Employees132,000
HQNew Brunswick, NJ, United States
ExchangeNYSE:JNJ
Websitejnj.com
LinkedInCompany Page
Therapeutic Focus
ImmunologyOncologyCardiovascularOtherDermatologyHematologyInfectious DiseaseMetabolic & EndocrinePsychiatryGastroenterologyNephrologyMusculoskeletalNeurologyOphthalmologyRespiratory
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cardiovascular(5 drugs)
—
—
—
4
3
Cardiovascular(5 drugs)
Dermatology(4 drugs)
—
—
1
3
—
Dermatology(4 drugs)
Gastroenterology(7 drugs)
2
—
—
4
1
Gastroenterology(7 drugs)
Hematology(3 drugs)
1
—
—
2
1
Hematology(3 drugs)
Immunology(10 drugs)
7
—
1
2
—
Immunology(10 drugs)
Infectious Disease(1 drug)
—
—
—
—
1
Infectious Disease(1 drug)
Musculoskeletal(2 drugs)
—
—
1
1
—
Musculoskeletal(2 drugs)
Neurology(5 drugs)
1
—
3
—
1
Neurology(5 drugs)
Oncology(52 drugs)
6
27
13
16
3
Oncology(52 drugs)
Ophthalmology(5 drugs)
—
—
2
2
1
Ophthalmology(5 drugs)
Psychiatry(3 drugs)
1
1
—
2
—
Psychiatry(3 drugs)
Respiratory(1 drug)
—
—
1
—
—
Respiratory(1 drug)
Unknown / Other(14 drugs)
2
2
2
9
2
Unknown / Other(14 drugs)
Regulatory
Regulatory Timeline
202513 events
FDANov 19
Darzalex — DARZALEX FASPRO
Application BLA761145
FDANov 14
Darzalex — DARZALEX FASPRO
Application BLA761145
FDANov 6
Darzalex — DARZALEX FASPRO
Application BLA761145
FDAOct 17
Balversa — BALVERSA
Application NDA212018
FDAOct 2
Tecvayli — TECVAYLI
Application BLA761291
FDASep 26
Tremfya — TREMFYA
Application BLA761061
FDASep 26
Tremfya — TREMFYA
Application BLA761061
FDASep 19
Tremfya — TREMFYA
Application BLA761061
FDASep 9
Gemzar — INLEXZO
Application NDA219683 (NDA)
FDAAug 19
Tecvayli — TECVAYLI
Application BLA761291
FDAJun 27
Gemzar — AVGEMSI
Application NDA219920 (NDA)
FDAJun 17
Tremfya — TREMFYA
Application BLA761061
FDAApr 29
Fabhalta — IMAAVY
Application BLA761430 (BLA)
20267 events
FDAMay 28
Darzalex — DARZALEX
Application BLA761036
FDAMay 28
Tremfya — TREMFYA
Application BLA761061
FDAMay 6
Tecvayli — TECVAYLI
Application BLA761291
FDAMar 17
Icotyde — ICOTYDE
Application NDA220149 (NDA)
FDAMar 5
Tecvayli — TECVAYLI
Application BLA761291
FDAFeb 12
Darzalex — DARZALEX FASPRO
Application BLA761145
FDAJan 27
Darzalex — DARZALEX FASPRO
Application BLA761145
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)